Regeneron Pharmaceuticals to buy 23andMe and its data
Digest more
The fall of 23andMe raises privacy concerns as Regeneron buys its genetic database for $256M after bankruptcy.
Regeneron Pharmaceuticals is acquiring the assets of 23andMe for $256 million, excluding its Lemonaid Health business, as the company faces layoffs and office closure due to financial struggles and a past cyberattack.
The bankruptcy follows a tumultuous 18 months for 23andMe, marked by declining sales ... grievances unrelated to the cyberattack, such as issues with DNA test results or the company's telehealth ...
Attorney General Gentner Drummond is alerting Oklahoma consumers in the wake of 23andMe having filed for bankruptcy protection last month. The genetic testing company, which collects and analyzes the genetic code of consumers,